Burns & Levinson Closes $ 4.2 Million Seed Funding for Anodyne Nanotech


This new class of micro-needles was invented at Tufts University and is now the core technology of Anodyne’s Hero Patch â„¢ platform, founded by Hojat Rezaei Nejad, Konstantinos Tzortzakis, and Jake lombardo. By incorporating a solvent-free bulk drug substance directly into microscopic pores, Anodyne can load unprecedented amounts of the drug onto each microneedle. When the micro-needle penetrates the skin, the drug dissolves in the patient’s interstitial fluid and is absorbed systemically.

“Our set of technologies solves many challenges that have hampered the transdermal delivery of large molecules at a clinically relevant dosage for decades. Anodyne Nanotech now focuses primarily on biologics, and we have shown the delivery of monoclonal antibodies and peptides in vivo. I believe our technology is a game changer and unprecedented on many levels, and we are continually working to expand and develop our capabilities, ”said Nejad, CTO of Anodyne Nanotech.

“We are proud to work with Anodyne,” Volman said. “Like a Tufts alumnus, it is particularly rewarding to work with companies that have been launched Tufts with such a star team of alumni. We look forward to working with Jake and Konstantinos and their impressive group of investors to build a strong business around their cutting edge science. “

Not only does the Anodyne technique allow unprecedented drug loading, but the use of the solid state form of the drug substance can also improve stability. This promise would bypass the need for cold chain distribution, a challenge of critical importance to developing countries, with economic benefits for the global biopharmaceutical industry. Anodyne has started collaborations with pharmaceutical companies to test specific biologics on the Hero Patch platform. The company plans to conduct clinical trials to characterize the bioequivalence, safety and tolerability of several Hero Patch products.

About Anodyne Nanotech

Anodyne Nanotech is a Bostonpreclinical-based biotechnology company developing differentiated transdermal forms of high-value drugs. The company’s patent-pending porous microneedle technology provides the first convenient and cost-effective platform, Hero Patch â„¢, to deliver clinically meaningful doses of macromolecules and small molecules.

About Burns & Levinson LLP

At Burns & Levinson, we provide high caliber, client-centric and results-oriented legal services to our regional, national and international clients. We are a full service law firm with over 125 lawyers Boston, Denver, Providence, and London. Our areas of expertise include: business / finance, commercial litigation, divorce / family law, venture capital / emerging companies, employment, estate planning, government investigations, intellectual property, mergers and acquisitions / private equity, probate litigation / trust and real estate. We partner with our clients to resolve their professional and personal legal issues in a collaborative, creative and cost-effective manner. For more information, visit Burns & Levinson at www.burnslev.com.


Amy blumenthal


Kristen weller

Blumenthal and associates

Director of Marketing and Business Development

(617) 879-1511

(617) 345-3555

[email protected]

[email protected]

SOURCE Burns and Levinson

Related links


Leave A Reply

Your email address will not be published.